EW

ACCE-researched
Edwards Lifesciences Corporation Common Stock
Healthcare · Medical Devices · NYSE · United States
$88.26+0.01%
Market cap $50.9BNext earnings 2026-10-29Updated Sep 20, 2026
FAIR VALUE · CONSENSUS
$88.26+0.0%
confidence-weighted across 4 of 6 models
Now $88.26
$88.26
$27.19$70.08
AvoidBronze57
Price vs fair value
74.7% above
-42.8% to fair value
ACCE score
55
out of 100
Analysts
44% buy
32 covering
P/E
52.5x
forward 26.0x
1-year return
+18.4%
Dividend yield
0.00%
Unlock the ACCE read
INVESTOR

Overview

⚠ Investor warnings · 3 flags
  • moderate
    Earnings growth lags revenue
    Revenue grew 16.7% YoY but earnings only 8.2%, suggesting cost pressures compressing net margin to 17.4%.
  • moderate
    Elevated trailing valuation
    P/E of 49.5x and EV/EBITDA of 32x leave little margin for error despite forward P/E improving to 30.6x.
  • moderate
    Insider selling only
    Last 10 disclosed transactions show $6.53M in sales, zero buys - no insider conviction at current price levels.
Reports in 38 days, last quarter beat by 0.1%.

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Price

+19.7% · 1Y

Valuation

INVESTOR
Full valuation engine INVESTOR FEATURE

Six independent models converge on one confidence-weighted fair value, with full methodology and editable assumptions.

  • +All six models: DCF, P/E and EV/EBITDA comps, Graham, dividend discount, residual income
  • +Scenario bands, sensitivity tornado, and the 5-year historical valuation range
  • +Editable DCF workbench with saved scenarios

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: conviction breakdown, earnings quality, score history, and backtested returns.

  • +Conviction score breakdown and earnings-quality grade
  • +Growth / value / quality / momentum component scores
  • +90-day score history and score-threshold backtests

Analysts

Wall Street consensus

Mixed44% buy · 32 covering analysts
● Strong buy 10● Buy 4● Hold 17● Sell 0● Strong sell 1
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO
Smart money tracking PRO FEATURE

Follow the institutions: 13F position changes, insider trades, and active 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Recent open-market insider transactions
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

This stock Peer Peer median weaker → stronger
P/Ebetter than 0% of peers
low 14.8x52.5xhigh 52.5x
ROEbetter than 0% of peers
low 9%9%high 38%
Div yieldbetter than 33% of peers
low 0.0%0.0%high 4.0%

Algorithmic peers (6)

TickerCompanyMcapP/EROED/EYieldQuality
SHL.DESiemens Healthineers$48.4B19.212.2%0.612.6%-Compare
BSXBoston Scientific Corporation Common Stock$62.8B17.615.3%0.470.0%-Compare
DXCMDexCom Inc. Common Stock$33.7B35.338.5%0.460.0%-Compare
GEHCGE HealthCare Technologies Inc. Common Stock $29.0B14.819.4%0.960.2%-Compare
SYKStryker Corporation Common Stock$105.5B29.116.5%0.711.2%-Compare
PHIA.ASKoninklijke Philips$24.2B18.910.2%0.624.0%-Compare

Sector report card

Where EW ranks against its sector peers on each metric.

Computing percentiles…

News and Record

Reports in 38 days, last quarter beat by 0.1%.

Press releases mentioning this company

Ask anything, Pro feature

Ask questions about this stock in plain language. Answered from company fundamentals + recent valuations.

PRO

Recent performance

1 week
+4.6%
1 month
-4.4%
3 months
+1.0%
6 months
+7.0%
YTD
+3.5%
1 year
+18.4%

SEC filings

40 filings
September 2026
Sep 14
Form 4Insider transactionPeriod 2026-09-11
Sep 14
Form 4Insider transactionPeriod 2026-09-13
Sep 11
Form 4Insider transactionPeriod 2026-09-11
37 more filings + AI summaries on Investor+.INVESTOR